Compare Mesoblast Limited (MESO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Redwire Corporation — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Redwire Corporation trades at $9.39 (market cap $2.05B). The key difference: Mesoblast Limited and Redwire Corporation are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| MESO | RDW | |
|---|---|---|
Market Cap | $2.17B | $2.05B |
Sector | Technology | Technology |
52-Week High | $20.96 | $25.90 |
52-Week Low | $12.88 | $5.06 |
Enterprise Value | $2.17B | $2.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
RDW trades at $8.60, down 1.78% on the day, with a bearish technical signal despite bullish oscillators. The company reported a net loss of $226.55 million in 2025, with negative margins and cash flow from operations. Recent news highlights a record $498 million backlog and contract wins, but concerns over dilution and losses persist. The stock is near its support levels with resistance at $9.
The outlook is mixed: strong analyst buy ratings and a $19 consensus price target suggest upside, but fundamental weaknesses and cash burn pose significant risks. Investment opportunity hinges on execution improving profitability, while key risks include continued losses and competitive pressures in the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
